Published in

Wiley, Colorectal Disease, 5(20), p. 371-382, 2018

DOI: 10.1111/codi.14103

Links

Tools

Export citation

Search in Google Scholar

Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).

Journal article published in 2018 by Rebecca Fish ORCID, C. Sanders, N. Ryan, S. Van der Veer ORCID, Andrew G. Renehan, P. R. Williamson
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Six Phase III randomized trials have determined the effectiveness of chemoradiotherapy as primary treatment for anal squamous cell carcinoma (ASCC), but outcomes reported in these trials varied widely, hindering evidence synthesis. To improve reporting in all future trials, we aim to develop a core outcomes set (COS). As the first stage of COS development, we undertook a systematic review to summarize the outcomes reported in studies evaluating chemoradiotherapy for ASCC.